AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00726739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic large multivalent immunogen vaccine
Description: Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI \[1 x 10\^7, 5-μm silica spheres\]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
Study NCT03627091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.
Study NCT01571479 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: 2- mini-instrument
Description: The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups.
Study NCT02294968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Startup (in Danish: Familieiværksætterne)
Description: Manualized parenting support program; see Center for Socialt Ansvar (2013)
Study NCT04087330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 Experimental group
Description: Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration.
Study NCT04087330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 Control group
Description: Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.
Study NCT02065544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral weight loss and exercise
Description: Weight loss and exercise counseling
Study NCT04101175 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of the procedure of abortion
Description: Observational study using questionnaires
Study NCT01984021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT01984021 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture
Study NCT01540643 — intervention group
Intervention type: DEVICE
Intervention: Iliac Leg Graft
Description: Zenith® Spiral-Z® AAA Iliac Leg Graft
Study NCT02784093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrograﬁn
Study NCT02784093 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: enemas
Study NCT01374061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical intubation
Description: Classical intubation
Study NCT01374061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLIDESCOPE
Description: GLIDESCOPE intubation
Study NCT02246972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: 6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
Study NCT02246972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: 6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
Study NCT00551928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: High dose Melphalan 200mg/sm with autologous stem cell support
Study NCT00551928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
Study NCT00551928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
Study NCT03627091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
Study NCT01833182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored home intervention
Description: The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
Study NCT01833182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham intervention
Description: We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
Study NCT02822820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure-Covidien
Description: Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
Study NCT02822820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RoBi forceps-Karl Storz
Description: Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
Study NCT01559220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Implanted device
Study NCT00465764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate protein infant formula
Description: Feed as per HCP directions
Study NCT00465764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Feed as per HCP directions
Study NCT04269460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]
Description: preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
Study NCT02301325 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking research cigarettes with or without NRT
Study NCT04097730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Ophthalmic
Description: Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
Study NCT04097730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Ophthalmic
Description: Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
Study NCT04097730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate Ophthalmic
Description: Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
Study NCT04097730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin Ophthalmic
Description: All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.
Study NCT04097730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riboflavin Ophthalmic
Description: All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.
Study NCT04097730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo
Description: Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.
Study NCT03462524 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: FEV1, FVC and DLCO will be assessed at baseline and one month post induction therapy. Radiation induced lung injury (RILI EORTC grade≥2), CCI, Clavien-Dindo, and pulmonary complications will be monitored. Changes in pulmonary function will be compared with cardiorespiratory symptoms and HR-QL among disease-free survivors.
Study NCT04195022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Restoration with Chemically activated Composite resin Alkasite
Description: Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
Study NCT04195022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Restoration with Bulk fill resin composite
Description: Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with bulk fill resin composite.
Study NCT01004237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin, valsartan, pravastatin+valsartan
Description: pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
Study NCT04714294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP737 or placebo
Description: HPP737 or placebo will be randomized to assign to subjects
Study NCT02303808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INHALATION WITH PEP DEVICE (Acapella Duet)
Description: Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01537861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT00158171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapies
Description: Nicotine gum 2 \& 4 mg dependent on baseline smoking rate
Study NCT00158171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 21, 14 or 7 mg patch dependent on baseline smoking rate
Study NCT00158171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: 400 mg
Study NCT01804270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
Study NCT01804270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
Study NCT04280263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
Study NCT04280263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
Study NCT02325141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: creation of a gastric tube of 100cc using a stapler.
Study NCT04299594 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
Study NCT02409953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lying in a bath during 2 hours
Study NCT02409953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lying in a bed during 2 hours
Study NCT00890981 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-resolution peripheral quantitative computed tomography (HR-pQCT)
Description: Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
Study NCT00890981 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry (DXA)
Description: Bone densitometry assessments of the forearm by DXA on day 1.
Study NCT00551928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
Study NCT00890981 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Denosumab
Description: Denosumab 60 mg subcutaneously every 6 months in the previous study
Study NCT00890981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo to denosumab subcutaneously every 6 months in the previous study
Study NCT03211403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640 or placebo once daily for a week
Study NCT03437304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunose™ FLU 1%
Description: Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
Study NCT03437304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunose™ FLU 2%, 200 μl
Description: Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
Study NCT03437304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunose™ FLU 2%, 300 μl
Description: Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
Study NCT03437304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza antigen
Description: Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
Study NCT03437304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl dosing volume 200 μl, intranasal administration x 2
Study NCT03437304 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: i.m comparator
Description: Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
Study NCT03437304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i.m comparator
Description: Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
Study NCT02469805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merional
Description: On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
Study NCT02469805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriomon
Description: Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
Study NCT02469805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
Study NCT02469805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovulation detection
Description: Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
Study NCT02469805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shepherd catheter
Description: Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
Study NCT04290728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apnea with high-flow nasal cannula
Description: Application of oxygenation with high-flow nasal cannula with a rate of 2L/kg/min
Study NCT04290728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apnea
Description: Apnea without any application of oxygenation
Study NCT00985036 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
Study NCT02126345 — intervention group
Intervention type: DEVICE
Intervention: MASTER SL femoral stem and DELTA TT acetabular cup
Study NCT03830723 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin delta
Description: Study medication doses during all 3 insemination will be personalized using a suggested algorithm